@ShahidNShah
The myNEO technology has been in development since 2017. In late 2018, the platform was incorporated into the myNEO company by Novalis Biotech Incubation. The founding team are accomplished entrepreneurs, continuously investing in new innovative technologies in the biotech industry that have the potential to create a sustainable impact on the long term.
The primary therapeutic focus of myNEO’s patient-specific tumour screening platform is personalised immunotherapy through neoantigen prediction. The ImmunoEngine enables determination of …
Posted Applications Immune System Diseases
Last Updated
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 4, 2024 at 5:17am